Patent Application
20100298434
The present invention relates to prevention or inhibition of dopaminergic cell death for neuroprotection and the protection, prevention, reduction of symptoms, delaying progression or treatment of Parkinson's disease. Particularly, the invention relates to methods for protecting and/or preventing dopaminergic cell death by administering to a subject in need thereof a compound, agent or composition inhibiting the translocation of Nur77 to the cytosol of dopaminergic cells. The invention also relates to methods for identifying such compounds or agents.
Parkinson's disease (PD) is a slow progressive neurodegenerative disorder. Most cases of PD are sporadic but rare familial forms of the disease do exist. The pathological hallmark of PD is a striking loss of dopamine (DA)-producing neurons in the substantia nigra (SN) causing DA depletion in the striatum. Although oxidative stress and mitochondrial dysfunction have been implicated in the process, the mechanisms underlying the selective death of nigral dopaminergic neurons are still unknown.
Nuclear receptors constitute a conserved family of ligand activated transcription factors regulating gene expression. Several groups have provided numerous evidence suggesting an important involvement of a subgroup of nuclear receptors specifically associated with DA neurotransmission in the developing and mature CNS (for review, see Lévesque and Rouillard, 2007). This subgroup includes the Retinoid X Receptor (RXR) and orphan members of the thyroid/steroid nuclear receptor family named the Nur family, which includes Nurr1, Nur77, and Nor-1. Nurs are classified as early response genes and are induced by diverse signals, including growth factors, cytokines, peptide hormones, neurotransmitters and stress. Their ability to sense and rapidly respond to changes in the environment seems to be a hallmark of this subgroup (Maxwell and Muscat, 2006).
Nurr1 co-localizes with tyrosine hydroxylase (TH) and is essential for the development of midbrain DA neurons whereas Nur77 and Nor-1 expressions appear complementary to Nurr1 distribution, being constitutively expressed in the striatum (STR) and nucleus accumbens (NAC) (Lévesque and Rouillard, 2007). RXR is expressed in both SN and DA target structures (NAC and STR) and is essential as a common heterodimerization partner of several nuclear receptors including Nurr1 and Nur77 (Perlmann and Jansson, 1995; Maira et al., 1999). Indeed, Nurr1, as well as Nur77, can affect transcription of target genes by working alone as monomers or as homodimers, or by forming functional transcriptional complexes through heterodimerization with RXR partners (Perlmann and Jansson, 1995; Maira et al., 1999). Numerous evidence suggest that impaired Nurr1 function may be associated with an increased vulnerability of DA neurons to degeneration in PD (Le et al., 1999; Eells et al., 2002; Wallen-Mackenzie et al., 2003; Le et al., 2003; Jiang et al., 2005) whereas both Nur77 and Nor-1 are important signals for apoptosis pathways outside the CNS (Cheng et al., 1997). Nur77 was reported to play either an anti-apoptotic or pro-apoptotic function depending on the cellular context (Cheng et al., 1997; Li et al., 2000; Suzuki et al., 2003; Zhang, 2007). Indeed, Nur77 controls both survival and death of cancer cells (Zhang, 2007). A wealth of recent evidence demonstrates that Nur77 activities are regulated through its subcellular localization (Zhang, 2007). Outside the brain, Nur77 functions as a survival factor in the nucleus. In contrast, it is a potent killer when migrating to the mitochondria, where it binds to Bcl-2 and converts Bcl-2 from a protector to a killer, triggering release of cytochrome c and activating the caspase cascade (Li et al., 2000; Martinou et al., 2000; Lin et al., 2004; Zhang, 2007). Nur77-induced apoptosis is rapid and robust (Zhang, 2007). The contrasting actions of Nur77 on apoptosis are modulated by its intracellular localization which in turn is dependent upon the nature of the signal to which the cell is exposed (Zhang, 2007).
The present invention therefore demonstrates that Nur77 is involved in neurotoxin-induced dopaminergic cell death via a mechanism involving its translocation from the nucleus to the cytoplasm. In vivo, Nur77 is rapidly and transiently induced after administration of the neurotoxin 6-hydroxydopamine (6-OHDA) in rats. The effects of MPTP are severely reduced in Nur77-deficient mice. In vitro, exposure of rat pheochromocytoma (PC12) cells to 6-OHDA or MPP+ induces Nur77 mRNA and protein expression and the translocation of Nur77 from the nucleus to the cytosol. Interestingly, 6-OHDA-induced cell death is significantly reduced by leptomycin B, a nuclear export inhibitor. We also report that docosahexaenoic acid (DHA), a RXR agonist, is able to prevent MPP+-induced PC12 cell death by blocking Nur77 nuclear export.
We hereby show that Nur77 can be induced in midbrain nigral dopamine neurons by administration of selective dopaminergic neurotoxins. Since Nur77 is modulated by a variety of signaling cascades including apoptotic and inflammatory signals, and its expression can be induced in the substantia nigra/ventral tegmental area (SN/VTA) complex. Also we have discovered that Nur77 is involved in the etiology and treatment of Parkinson's disease and that Nur77 and RXR, its heterodimerization partner can be targeted to protect nigral dopamine neurons from early cell death and therefore prevent neurodegenerative disorders such as Parkinson's disease.
It is therefore a first aspect, of the present invention to provide a method for identifying a compound for protecting/preventing dopaminergic cell-death, this method comprising the steps of assessing the ability of a compound to achieve at least one of: a) inhibit or prevent the expression of Nur77 in the nucleus of nigral dopamine neurons; b) inhibit or prevent the translocation of Nur77 to the cytosol of nigral dopamine neurons; c) increase or promote the transactivation of RXR in the nucleus of nigral dopaminergic neurons; or d) increase or promote the formation of RXR-Nur77 heterodimers in the nucleus of nigral dopaminergic neurons; whereby the ability of said compound to achieve at least one of said goal listed in a) to d) is an indication that said compound is a potential drug for preventing or inhibiting dopaminergic cell-death.
It is therefore a second aspect of the present invention to provide a method for protecting or preventing dopaminergic cell-death comprising the step of inhibiting or preventing Nur77-dependent apoptosis.
It is therefore a third aspect of the present invention to provide a method for the prevention of or protection from Parkinson's disease in a human comprising administering to the human a pharmaceutically effective amount of a compound or composition protecting or preventing Nur77-dependent apoptosis.
Having thus generally described the aspects of the invention, reference will now be made to the accompanying drawings, showing by way of illustration, particular embodiments thereof, and in which:
The abbreviation “6-OHDA” means 6-hydroxydopamine.
The abbreviation “DHA” means docosahexaenoic acid.
The abbreviation “MPP+” means 1-methyl-4-phenylpyridinium ion. The abbreviation “MPTP” means 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. The term Nur77 means a protein defined by sequence NM002135 in GENBANK®.
The terms “dopaminergic cells”; “nigral dopamine cells”, “dopamine neurons”, are all used interchangeably.
In this first aspect, there is provided a method for identifying a compound for protecting from, preventing or inhibiting dopaminergic cell-death, said method comprising the step of contacting a candidate compound with Nur-77 or a Nur-77-producing cell to evaluate the ability of said compound to bind to Nur77 or inhibit Nur77-dependent apoptosis wherein the ability of said compound to bind Nur77 or inhibit Nur77-dependent apoptosis is an indication that said compound is a potential drug for preventing or protecting from dopaminergic cell-death.
Particularly, the method comprises the step of contacting a candidate compound with Retinoid X Receptor (RXR) to evaluate the ability of the compound to bind to RXR (RXR-cpd), wherein the ability of the compound to bind to Nur77 is an indication that said compound is a potential drug for preventing/protecting dopaminergic cell-death.
More particularly, the method comprises the steps of: a) contacting a candidate compound with Retinoid X Receptor (RXR) to evaluate the ability of the compound to form a transcriptional complex with RXR (RXR-cpd); and b) assessing the ability of said transcriptional complex to inhibit the translocation of Nur77 (or Nur77-RXR heterodimer) to the cytosol of said dopaminergic cells; wherein the ability of the complex to inhibit Nur77 translocation is an indication that said compound is a potential drug for preventing/protecting dopaminergic cell-death.
Particularly, this method may be carried out in vitro using recombinant protein systems. Alternatively, this method may be carried out in situ using cells that express RXR and Nur77. These cells may express these proteins constitutively or transiently. Particularly, these cells are dopaminergic neurons in culture or PC12 cells. More particularly, these cells are PC12 cells.
The present invention therefore provides a method for protecting/preventing dopaminergic cell-death comprising the step of inhibiting Nur77-dependent apoptosis. Particularly, the invention provides a method for protecting/preventing dopaminergic cell-death comprising the step of inhibiting the expression of Nur77 in the nucleus of nigral dopamine neurons. More particularly, there is provided a method for protecting/preventing dopaminergic cell-death comprising the step of inhibiting the translocation of Nur77 to the cytosol of nigral dopamine neurons. Still, particularly, the invention provides a method for protecting/preventing dopaminergic cell-death comprising the step of increasing the transactivation of RXR in the nucleus of nigral dopaminergic neurons. Alternatively, there is provided a method for protecting/preventing dopaminergic cell-death comprising the step of increasing or promoting the formation of RXR-Nur77 heterodimers in the nucleus of nigral dopaminergic neurons.
In a third aspect, the invention provides a method for the prevention of Parkinson's disease in a subject comprising administering to the subject a pharmaceutically effective amount of a compound inhibiting Nur77-dependent apoptosis. Particularly, the compound inhibiting Nur-77 dependent apoptosis is a Retinoid X Receptor ligand. More particularly, the RXR ligand induces the transactivation of the RXR in the nucleus of nigral dopamine neurons favoring the formation of a RXR-Nur77 complex. More particularly, the RXR ligand blocks the translocation of the RXR-Nur77 complex to the cytosol of nigral dopamine neurons.
Particularly, the subject is a human.
Particularly, the treatment may be administered before or after symptoms appear in the human. Particularly, the symptoms of Parkinson's disease can be one or more than one of the following: slowness of movement, compromise of balance, muscle rigidity and tremor.
Particularly, the compound administered is an RXR ligand. More particularly, the RXR ligand is docosahexaenoic acid (DHA) or its metabolites or derivatives such as, for example, DEA (docosaenoic acid).
Parkinson's disease is a progressive neurodegenerative disorder characterized by a selective death of nigral dopamine neurons. Currently, the mechanisms underlying the neurodegenerative process remain unclear. Nur77 is a transcription factor closely associated to dopamine neurotransmission in the mature brain. However, Nur77 is also a potent signal for apoptosis outside the CNS. This nuclear receptor is a survival factor when located in the nucleus whereas it is a potent killer when migrating to the mitochondria. Applicant reports that Nur77 is directly involved in dopamine cell death induced by specific neurotoxins. Indeed, Nur77 is rapidly and transiently induced in midbrain dopamine neurons after the administration of 6-OHDA in vivo. In addition, in vitro data demonstrate that Nur77 is involved in cell death after 6-OHDA and MPTP exposure via a mechanism involving its translocation from the nucleus to the cytosol. 6-OHDA- and MPTP-induced cell death in vitro is then significantly reduced by administration of docosahexaenoic acid (DHA), a polyunsaturated fatty acid binding the Retinoid X Receptor (RXR). This nuclear receptor interacts with Nur77 by forming transcriptional complexes through heterodimerization. Applicant also demonstrates that transactivation of RXR by DHA silences the translocation of Nur77 to the cytosol thereby inhibiting Nur77-dependent apoptosis. Altogether, these data suggest that Nur77 is involved in dopamine cell death via a mechanism that can be blocked by the administration of DHA. These novel findings open the way to new therapeutic strategies that may slow or stop the progression of Parkinson's disease.
The present invention to provide a method for protecting/preventing dopaminergic cell-death comprising the step of inhibiting the translocation of Nur77 in the cytosol. This can be achieved by a) increasing the transactivation of RXR in the nucleus of nigral dopaminergic neurons; b) increasing or promoting the formation of RXR-Nur77 heterodimers in the nucleus of nigral dopaminergic neurons; or c) inhibiting the translocation of Nur77 from the nucleus to the cytosol. Either one, or all of these mechanism may be exploited in the search for a therapeutic agent effective against Parkinson's disease.
6-hydroxydopamine Lesions in Rats
Fifteen male Sprague—Dawley albino rats (Charles River, Montreal, Canada) weighing 250-275 g at the beginning of the experiment were used in this study. They were housed two per cage in a temperature-controlled environment maintained under a 12-h light/dark cycle with ad libitum access to food and water. Handling of the rats was performed in accordance with the Canadian Guide for the Care and Use of Laboratory animals and all procedures were approved by the Institutional Animal Care Committee of Laval University. All efforts were made to minimize the number of animals used and their suffering. Rats were anaesthetized in an induction chamber with 4% isoflurane in 95% O2/5% CO2 before being transferred to a stereotaxic frame and maintained at 1.5-3% isoflurane. A sagittal cut exposed bregma and a hole was drilled. 6-OHDA was injected into the right striatum (AP: 0.6 with respect to bregma, L: 3.0 and V: 4.5) or into the right median forebrain bundle (AP: −4.3; ML: 1.4; and DV: 8.0 (Paxinos and Watson, 1986)). The neurotoxin 6-OHDA (12 μg/3 μl) was dissolved in saline containing ascorbic acid (0.1%) and injected at a rate of 1 μl/min and the syringe was left in place for an additional 5 min to allow diffusion of 6-OHDA away from the needle tip. Rats were anaesthetized with CO2 and killed by decapitation at 3, 9 24, 72 and 120 hrs after 6-OHDA administration.
Cryostat-cut brain sections (12 μm) were mounted on Superfrost slides (Fisher Scientific, Toronto, ON, Canada) and stored at −80° C. Specific [35S]UTP-labeled complementary.
RNA (cRNA) probes were used and preparation of the Nur77 probe was performed as described previously (Beaudry et al., 2000). The antisense cRNA probe for Nur77 stems from a 2.4-kb EcoRI fragment of a full-length rat Nur77 cDNA subcloned into pBluescript SK-1 and linearized with BamHI. The single-stranded riboprobe complementary to the RNA of interest was synthesized and labeled using Promega riboprobe kit (Promega, Madison, Wis.), [35S]UTP (Perkin Elmer Inc., Canada), and the RNA polymerase T3. The hybridization technique was performed as previously described (Beaudry et al., 2000; Langlois et al., 2001). Briefly, brain sections were fixed in a 20-min paraformaldehyde bath (4% paraformaldehyde in 100 mM phosphate buffer) and then rinsed twice in phosphate buffer (100 mM) for 5 min. Subsequently, a triethanolamine incubation (TEA 100 mM, pH 8.0) and a 10-min acetylation bath (0.25% acetic anhydride, TEA 100 mM) followed. Slides were finally rinsed in standard saline citrate (SSC) (300 mM NaCl, 30 mM sodium citrate) and dehydrated in increasing concentrations of ethanol. The 35S-labeled riboprobe was added to a concentration of 2×107 cpm/ml in a hybridization mix (Denhart's solution, dextran sulfate, and 50% deionized formamide) and heated at 65° C. for 5 min. Each slide was covered up with 50 μl of the hybridization solution and coverslipped. The hybridization took place overnight at 58° C. on a slide warmer. After hybridization, slides were soaked in SSC (600 mM NaCl, 30 mM sodium citrate) for 30 min to remove coverslips and then washed in four subsequent SSC baths. Afterward, slides spent 30 min in a 37° C. incubation buffer with RNAse A (2 mg/100 ml). A series of SSC baths with dithiothreitol (1 mM) followed, one of which was at 55° C. for 30 min. Finally, tissues were dehydrated in ethanol, dried up, and apposed to a Biomax MR film (Kodak). Autoradiograms were developed approximately 48 h later. Subsequently, sections were dipped in NTB2 nuclear emulsion (diluted 1:1 with distilled water; Kodak). Slides air-dried for 4 h and stored in the dark for 5 days at 4° C. The emulsion was then developed in D19 developer (Kodak) for 3.5 min at 14-15° C. and fixed in Rapid Fixer (Kodak) for 5 min. Thereafter, brain tissue was rinsed in running distilled water for 1-2 h and dehydrated trough graded concentration of alcohol, cleared in xylene and coverslipped with DPX.
The brain sections were mounted on gelatin-coated slides (Brain Research Laboratories, Newton, Mass.) and air-dried overnight. They were dehydrated in ascending grades of ethanol, hydrated in descending grades of ethanol and finally rinsed in milliQ water. Afterwards, the sections were dipped in a 0.06% potassium permanganate solution bath for 10 min and washed in milliQ water. They were then incubated in a milliQ solution containing 0.0002% (v/v) DAPI (Molecular Probes, Eugene, Oreg.), 0.1% (v/v) acetic acid glacial and 0.0004% (v/v) Fluoro-Jade B (Chemicon, Temecula, Calif.) for 20 min (Schmued et al., 1997). After a few rinses in milliQ water, they were completely air-dried, dipped in xylene and coverslipped with DPX. Degenerating neurons and fibers appeared green and nuclei emerged blue in fluorescence.
Wild-type (Nur77(+/+)) male (C57BL/6, weighing 20-25 g) mice were purchased from Charles River, Canada. Nur77 knockout (Nur77(−/−)) mice were developed and graciously provided by Dr Jeff Milbrandt at the Washington University, St. Louis, Mo., USA (Lee et al., 1995). These mice are healthy and reproduce normally (Crawford et al., 1995; Lee et al., 1995). They were produced in a mixed background and have been backcrossed into the C57BL/6 strain for at least ten generations to reduce genetic background heterogeneity (Jeff Milbrandt, personal communication). We maintain a Nur77(−/−) mouse colony at the animal care facility of our research center. Young adult Nur77(−/−) male mice weighing 20-25 g were used for present experiments. All mice were housed three or four per cage in a temperature-controlled environment and maintained under a 12-h light-dark cycle with ad libitum access to food and water.
In total, 17 mice (8 Nur77 (+/+) and 9 Nur77 (−/−)) received seven intraperitoneal (i.p.) injections of MPTP-HCl (20 mg/kg free base; Sigma, St. Louis, Mo.) dissolved in NaCl 0.9%. MPTP was administered twice on the first 2 days of the experimental protocol at an interval of 12 h and once a day on 3 subsequent days (Tremblay et al. 2006; Gibrat et al., 2010). Animals were ultimately sacrificed 14 days after the last injection. An identical number of mice (8 Nur77 (+/+) and 9 Nur77 (−/−)) received i.p. saline injections. All animals were sacrificed 14 days after the last injection.
Animals were sacrificed under deep anesthesia with sodium pentobarbital [60 mg/ml, i.p. (0.1 ml/100 g)] and perfused via intracardiac infusion with heparinized saline (0.9%) followed by 4% paraformaldehyde (PFA) with Borax (sodium tetraborate) in milliQ water, pH 9.5, 14 days after the last MPTP injection. After intracardiac perfusion, brains were collected and post-fixed in 4% PFA for 6 h and transferred to 20% sucrose in 0.1M phosphate buffer saline (PBS) for cryoprotection. Coronal brain sections of 30 m thickness were cut on a freezing microtome (Leica Microsystems, Montreal, Que.), serially collected in anti-freeze solution (monophosphate sodium monobasic 0.2 M, monophosphate sodium dibasic 0.2 M, ethylen glycol 30%, glycerol 20%). At the beginning of each immunostaining protocol, sections were washed in PBS 0.1M and then placed in 3% peroxide for 30 min at room temperature (RT). Slices were transferred in 0.1M PBS for several washes and then preincubated in a 0.1M PBS solution containing 0.1% Triton X-100 (Sigma) and 5% normal goat serum or normal donkey serum (NGS or NDS) for 30 min at RT. Sections were incubated overnight at 4.0 with a rabbit anti-TH antibody (Pel-Freez, Rogers, AR; 1:5000). After overnight incubation at 4° C. with the primary antibody, sections were washed in PBS 0.1M and incubated for 1 h at RT in a PBS solution containing 0.1% Triton X-100, 5% NGS or NDS, and biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlington, ON; 1:1500) for thyronine hydrolxylase (TH). Following three washes in PBS, sections were placed in a solution containing avidin-biotin peroxidase complex (ABC Elite kit; Vector Laboratories, Burlington, ON) for 1 h at RT. The bound antibodies were visualized by placing the sections in a Tris 0.05M buffer solution containing 0.5 mg/ml of 3,3′ diaminobenzidine tetrahydrochloride (DAB; Sigma) and 0.1% of 30% hydrogen peroxide (Sigma) at room temperature. The reaction was stopped by washing in 0.05M Tris buffer and subsequent PBS washes. Sections were then mounted on gelatin-coated slides and counterstained with cresyl violet (Sigma). Finally, all sections were ultimately air-dried, dehydrated in ascending grades of ethanol, cleaned in xylene and coverslipped with DPX mounting media (Electron Microscopy Science, Hatfield, Pa.).
The loss of DA neurons was determined by counting TH-immunoreactive cells under bright-field illumination. After delineation of the SNpc at low magnification (10×), three sections from the entire region were sampled at higher magnification (20×) using Stereo investigator software (Microbrightfield, Colchester, Vt.) attached to a E800 Nikon microscope (Nikon Instruments, Toronto, Canada). Section sampling was performed based on the achievement of the desired coefficient of error (Glaser and Glaser, 2000), which ensured the correct representations of cell counts on three sections of the same brain (AP levels: −5.3 to −6.04 mm) (Paxinos and Watson, 1986). The optical fractionator method (Glaser and Glaser, 2000) was used to count TH-positive (TH+ and cresyl violet+neurons) and TH-negative (cresyl violet+only) expressing cells. The entire depth of the field was sampled ignoring the upper and lower 2 m to avoid counting cells that might be missing nuclei. Cell counts were performed blindly by two independent investigators. Note that these analyses were restricted to the SNpc and thus excluded the ventral tegmental area (VTA). The average density of TH-immunoreactive expressing neurons per section, derived from the analysis of three SNpc sections, was ultimately plotted.
Fetal calf and horse serums were obtained from Life Technologies (Ontario, Canada). Culture medium RPMI 1640, MPP+, gentamicin, and GenElute Total mammalian RNA extraction kit were purchased from Sigma Chemicals (Ontario, Canada). RT reagents were purchased from New England Biolab (NE, USA). PCR reagent HotMasterMix was purchased from Eppendorf (Westbury, N.Y., USA). Polyclonal rabbit anti-Nur77 antibody (epitope corresponding to amino acids 59-269 of mouse Nur77) was purchased at Santa Cruz Biotechnology (Santa Cruz, Calif., USA).
Monoclonal mouse anti-TH antibody (clone 2) was purchased from Sigma Chemicals (Ontario, Canada). Polyclonal rabbit anti-HDAC1 antibody (epitope corresponding to amino acids 450 to C-terminus of human histone deacetylase 1 (HDAC1) was purchased from Abcam (Cambridge, Mass., USA). Anti-Rabbit Cy3-conjugated secondary antibody was purchased from Jackson ImmunoResearch (West Grove, Pa., USA) and Prolong® Antifade from Molecular Probes (Eugene, Oreg., USA).
PC12 cells were obtained from ATCC CRL 1721 (VA, USA) and were grown in phenol red-free RPMI 1640 medium supplemented with 5% fetal calf serum (FCS), 10% horse serum and gentamicin (50 μg/ml). They were cultured on Primaria 6-well plates (BD Falcon, Ontario, Canada) for RT-PCR experiments and immunoblotting; on Primaria 96-wells plates for LDH cytoxicity experiments and finally on poly-L-lysine-coated circular glass coverslips for immunocytofluorescence assays. Cells were fed fresh medium every 3 days and maintained at 37° C. in a humidified 5% CO2 atmosphere. Treatment medium included RPMI 1640, 1% FCS (charcoal stripped to remove steroids), gentamicin, 6-OHDA (10-30 μM). Control conditions were without toxin. The 6-OHDA concentration used (30 μM) was chosen since it did not induce more than 70% cell death after 24 h, as revealed by dose-response and time course studies (data not shown). For the present study, kinetic time periods were: 0 h, 3 h, 6 h, 9 h, 12 h and 24 h. After each experiment, culture medium was harvested for cytotoxicity detection and cells were collected for RT-PCR and ICF/Fractioning (Gelinas & Martinoli 2002; Gagne et al. 2003; Gelinas et al. 2004; Chiasson et al. 2006).
Cytotoxicity was evaluated by colorimetric assay based on the measurement of lactate deshydrogenase (LDH) activity, as previously described (Chiasson et al. 2006). Briefly, media were collected and centrifuged at 800×g at 4° C. for 2 min. The cell-free supernatant (100 μl) was then used to determine LDH activity by measuring the absorbance at a wavelength of 490 nm (A490) on a microplate reader (Multiscan Ascent Microplate reader, Thermolab System, Franklin Mass.) according to the working procedures of Roche's protocol. Total cellular LDH was determined by lysing cells with 1% Triton X-100. The A490 is proportional to the number of viable cells in the culture (Roehm et al. 1991).
Total RNA was extracted with Sigma's GenElute Mammalian Total RNA extraction kit. RNA was assayed for each condition, and reverse transcriptase (RT) was performed with 1 μg total RNA. PCR was then performed with 10% of the RT product, amplified with specific primers and HotMasterMix. For specific semiquantitative RT-PCR of transcripts, forward and reverse primers were synthesized at Sigma Genosys (The Woodlands, Tex., US) and are shown in Table 1.
The standardized amplification protocol consisted of an initial denaturation step at 94° C. for 2 min, followed by 25 sequential cycles of 94° C. for 1 min, specific annealing temperature (Table 1) for 1 min and 65° C. for 1.5 min, with a final extension of 7 min at 65° C. Amplification was carried out in a Perkin Elmer GeneAmp PCR System 2400 thermal cycler. To ensure that quantification was achieved in an exponential phase, a range of target and standard amounts were amplified over a range of cycles. The final number of cycles was chosen as the time in which the amplified products were still accumulating in a logarithmic fashion, i.e. the system was in the exponential phase, as already described (Rousseau et al. 2002). 10 μl of the PCR products were analyzed by electrophoresis on 1.5% agarose gel in 1×TAE running buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.0) and stained with ethidium bromide. Images were acquired with a Fluor SP Imager from Alpha Innotech, and analyzed with their Fluor Chem SP software. Every analysis was correlated with the amplicon of ribosomal 18S subunit as internal amplification controls.
PC12 cells were grown and treated on circular glass coverslips, then fixed in 4% paraformaldehyde for 1 hour at 4° C. Immunofluorescence detection sequence was as follows: primary antibodies (1:1000, 1 h at RT), then slides were washed with PBS and stained with a fluorescent dyed secondary antibody (Cy3, 1:50) for 2 h at RT. 4′,6-Diamidino-2-phenylindole (DAPI) was used to counterstain all nuclei. They were washed 3 times with PBS. Finally, slides were mounted with the Prolong® Antifade Kit (Molecular Probes, Eugene, Oreg.). Images were acquired with an Olympus IX-70 inverted microscope with a high-pressure mercury burner and necessary filter cubes (Olympus U-MNUV, U-MNIBA and U-MWIG), and were analyzed with Bio-Rad's QuantityOne software. TUNEL assay was performed on the same slides as with the immunofluorescence (Heatwole 1999).
PC12 cells were grown and treated in 6-wells plates. We used a nuclear extraction kit (Active Motif, Carlsbad, Calif.) to separate cytoplasmic protein content from nuclear protein content. Briefly, cells were washed in wells with a mixture of PBS and phosphatase inhibitors, and then harvested in centrifuge tubes. Hypotonic buffer swelled cytoplasmic membrane, which an afterward mild detergent ruptured.
Centrifugation at 14,000×g pelleted the intact nuclei, and soluble material was preserved as the cytoplasmic fraction. Nuclei were the lysed with the provided lysis buffer. Protein dosage was performed with a bicinchoninic acid (BCA)-based SDS-compatible Protein Assay Kit (Pierce, Rockfort, Ill.) on each fraction of each sample.
Equal amounts of nuclei or cytoplasmic protein fractions were loaded onto a 10% polyacrylamide-SDS gel. After electrophoretic separation (180 volts, 45 min.) the polyacrylamide gels were transferred onto nylon (PVDF) membranes (0.22 μm pore size, Bio-Rad) at 50 V for 2 h. The membranes were blocked with 5% non-fat powder milk for 1 h. Immunoblotting was probed with primary antibody for at least 2 h. Dilution of anti-Nur77, anti-TH and Anti-HDAC1 was 1:1000, 1:1000 and 1:1250, respectively. Horseradish peroxydase (POD)-conjugated secondary antibody was added for 2 h. Immunopositive signal was visualized with an enhanced chemiluminescence method (Roche, Que., Canada) and were acquired with a Fluor SP Imager from Alpha Innotech. Quantitative analysis was performed with the Fluor Chem SP software.
The statistical significance was assessed against control using unpaired Student test with a two-tailed P value using GraphPad InStat version 3.06 for Windows© (San Diego Calif. USA, www.graphpad.com). Data are expressed as mean±S.E.M from 3 to 10 independent experiments. Stars (*) are for statistical difference between treatment and respective control condition.
In
In
In
In
In
In
In
In
As represented in
The origin of cell degeneration in Parkinson's disease is largely unknown. This study provides several lines of evidence in vivo and in vitro that Nur77 is involved in dopaminergic cell death via its upregulation and a mechanism involving its translocation from the nucleus to the cytosol. We also provide evidence that Nur77-dependent apoptosis can be significantly reduced by silencing its translocation to the cytosol.
Numerous data suggest that impaired Nurr1 function may be associated with an increased vulnerability of dopamine neurons to degeneration in PD (Le et al., 1999; Le et al., 2003; Eells et al., 2002; Jiang et al., 2005) and Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons (Kadkhodaei et al., 2009). However, little is known about the role of Nur77 despite the fact that it is an important signal for apoptosis pathways outside the brain (Cheng et al., 1997). There is a possibility that Nur77 might be involved in environmental-induced dopamine-neuronal death since this nuclear receptor/transcription factor is modulated by a variety of signaling cascades (Fass et al., 2003; Bourhis et al., 2008; Kovalovsky et al., 2002; Darragh et al., 2005) and its expression can be induced in the substantia nigra/ventral tegmental area complex (Maheux et al., 2005; Bourhis et al., 2008). Although, Nur77 is not normally expressed in the substantia nigra/ventral tegmental area complex, we demonstrate here that Nur77 is rapidly and transiently induced in midbrain dopaminergic neurons after intracerebral 6-OHDA administration in rats. Nur77 mRNA is induced as early as 3 h after 6-OHDA administration. Its regulation in this brain area by 6-OHDA is in accordance with recent data demonstrating that Nur77 can be induced in the SN/VTA complex by antipsychotic drugs (Maheux et al., 2005; Bourhis et al., 2008). Nur77 induction in midbrain dopaminergic neurons by the neurotoxin 6-OHDA raises the possibility of its involvement in dopaminergic cell death. Interestingly, Fluoro-Jade staining, a marker of neuronal death (Schmued and Hopkins, 2000), is also observed at 3 h after intracerebral 6-OHDA administration and is maximal at 48 h suggesting similar time courses for Nur77 expression and signs of apoptosis. A direct involvement of Nur77 in neurotoxin-induced neuronal death is also supported by the fact that the neurotoxic effects of a MPTP systemic regime are severely reduced in Nur77 (−/−) mice.
Cytotoxicity in undiffererentiated and differentiated PC12 cells is a suitable in vitro model of Parkinson's disease (Hirata et al., 2006; Yamamoto et al., 2007). PC12 cells synthesize, store, release and metabolize dopamine. We show here that Nur77 mRNA is rapidly and significantly upregulated in PC12 cells after exposure to 6-OHDA. This upregulation of Nur77 begins as early as 3 h following exposure to the neurotoxin and precedes the signs of apoptosis which are significantly elevated starting at 6 h. The upregulation of Nur77 is accompanied by significant changes in the levels of other apoptotic genes. Levels of Nur77, p53 and Bax rose at 3 h after exposure to the neurotoxin and remained elevated up to 24 h whereas the expression of Bcl-2, an anti-apoptotic marker, decreased to 50% of the control level at 9 h and remained down-regulated at 12 and 24 h. At this time period, more than 90% of the cells show signs of apoptosis (TUNEL/DAPI) and Nur77 is co-expressed with these apoptosis markers in a very high percentage of these cells.
As recently reported in SH-SY5Y cells (No et al., 2010), we report that upon the treatment of PC12 cells with 6-OHDA, there is a rapid translocation of the Nur77 protein from the nucleus to the cytosol. The drastic change in the subcellular distribution of Nur77 correlates well with the time-course of 6-OHDA-induced neurotoxicity. Interestingly, 6-OHDA-induced Nur77 nuclear export in PC12 cells is blocked by pre-treatment with leptomycin B, a nuclear export inhibitor. This pre-treatment induced a significant reduction 6-OHDA-induced cell death as demonstrated here and in another cell line (No et al., 2010). This is in accordance with results in cancer cells, where Nur77 functions as a survival factor in the nucleus and in contrast, as a potential cell death signal when migrating to the mitochondria. At this subcellular localization, it binds to Bcl-2 and converts Bcl-2 from a protector to a killer by triggering cytochrome C release and activating the caspase cascade (Zhang, 2007; Li et al., 2000; Martinou et al., 2000; Lin et al., 2004). In cancer cells, Nur77-induced apoptosis is rapid and robust. The contrasting actions of Nur77 on apoptosis are modulated by its intracellular localization which in turn is dependent upon the nature of the signal to which the cell is exposed (Zhang, 2007). Nur77 subcellular localization is controlled via nuclear localization and nuclear export signals (Hsu et al., 2004). The DNA binding domain (DBD) of Nur77 contains two nuclear localization signals whereas the ligand binding domain (LDB) contains three leucine-rich putative nuclear export signals, which are critical for exit from the nucleus. Nur77 is a direct target of various signaling cascades which can lead to its phosphorylation which in turn might impact on its activity, subcellular localization and receptor heterodimerization. Data in the literature suggest that extracellular signal-regulated kinase2 (ERK2) might be involved in Nur77-mediated cell death (Castro-Obregon et al., 2004) and that ERK1/2 is implicated in 6-OHDA neurotoxic effects in the brain (Chu et al., 2004; Kulich and Chu, 2003).
RXR is an essential heterodimerization partner for both Nur77 and Nurr1 (Maira et al., 1999; Perlmann and Jansson, 1995). High levels of the RXRγ1 isoform are found in the substantia nigra (Langlois et al., 2001; Krezel et al., 1999; Saga et al., 1999). Recent data indicate that activation of RXR receptors increases dopaminergic cell survival in models for Parkinson's disease (Friling et al., 2009; Backman et al., 2003). DHA is a polyunsaturated fatty acid that acts as an endogenous RXR ligand in the brain (Mata de Urquiza et al., 2000). It has been recently shown that a diet rich in DHA exerts a neuroprotective action against MPTP-induced toxicity by protecting against the neurotoxin-induced decrease of several dopaminergic markers into the striatum and the substantia nigra (Bousquet et al., 2007). In accordance, we show here DHA is able to prevent 6-OHDA and MPP+-induced cell death in PC12 cells by blocking Nur77 translocation from the nucleus to the cytosol. This is consistent with data in the literature indicating that RXR modulates Nur77 subcellular localization in a ligand-dependent manner. In the presence of RXR transactivation by agonists, Nur77-RXR heterodimers are formed via heterodimerization sites in their ligand-binding domains (LBDs), resulting in chromatin-binding heterodimers. This conformation silences the nuclear export signal (NES), thus maintaining nuclear localization (Zhang, 2007). In accordance with this, RXR agonists suppress apoptosis by inhibiting mitochondrial targeting (Cao et al., 2004). However, the possibility that the Nur77-RXR heterodimer complex can also be translocated outside the nucleus remains. In this case, it has been proposed that Nur77 cannot induce apoptosis due to the inability of Nur77-RXR heterodimer to interact with the mitochondria, in contrast to Nur77 alone (Kang et al., 2000).
Nur77 is rapidly and transiently induced in midbrain dopamine neurons after the administration of 6-OHDA in vivo.
Nur77 is involved in cell death after 6-OHDA and MPTP exposure via a mechanism involving its translocation from the nucleus to the cytosol.
Transactivation of RXR by DHA silences the translocation of Nur77 to the cytosol thereby inhibiting Nur77-dependent apoptosis.
Altogether, these data suggest that Nur77 is involved in dopamine cell death via a mechanism that can be blocked by the administration of DHA. These novel findings open the way to new therapeutic strategies that may slow or stop the progression of Parkinson's disease.
This application claims priority from U.S. provisional patent application 61/180,198 filed on May 21, 2009.
| Number | Date | Country | |
|---|---|---|---|
| 61180198 | May 2009 | US |
